Stoke Therapeutics (STOK) Share-based Compensation (2018 - 2026)
Stoke Therapeutics (STOK) posted quarterly Share-based Compensation of $8.8 million for Q1 2026, up 29.62% year-over-year from $6.8 million in Q1 2025, and down 10.77% quarter-over-quarter from $9.8 million in Q4 2025.
Stoke Therapeutics (STOK) Share-based Compensation (2018 - 2026) Analysis & Trends
Stoke Therapeutics' Share-based Compensation history runs 9 years deep, the most recent figure standing at $8.8 million for Q1 2026.
- In Q1 2026, Share-based Compensation rose 29.62% year-over-year to $8.8 million; the TTM figure through Mar 2026 stood at $33.4 million (up 15.64% YoY), while the FY2025 annual figure was $54.8 million, up 83.28% from the prior year.
- Share-based Compensation for Q1 2026 stood at $8.8 million, down from $9.8 million in the prior quarter.
- The five-year high for Share-based Compensation was $36.1 million in Q2 2025, with the low at $5.0 million in Q1 2022.
- The 5-year median for Share-based Compensation is $6.8 million (2025), against an average of $8.5 million.
- The sharpest annual moves came in 2022 and 2024: Share-based Compensation jumped 6118.75% in 2022, then fell 8.1% in 2024.
- Stoke Therapeutics' Share-based Compensation stood at $5.8 million in 2022, then grew by 3.8% to $6.1 million in 2023, then climbed by 18.34% to $7.2 million in 2024, then jumped by 36.84% to $9.8 million in 2025, then fell by 10.77% to $8.8 million in 2026.
- Business Quant data shows STOK's Share-based Compensation at $8.8 million in Q1 2026, $9.8 million in Q4 2025, and $8.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Stoke Therapeutics | 1.95 Bn | 1.66 Bn | - | 83.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 83.10 Mn |
| Jun 30, 2026 | 83.10 Mn |
| Mar 31, 2026 | 8.75 Mn |
| Mar 31, 2026 | 8.75 Mn |
| Dec 31, 2025 | 9.81 Mn |
| Dec 31, 2025 | 9.81 Mn |
| Sep 30, 2025 | 8.04 Mn |
| Sep 30, 2025 | 8.04 Mn |
| Jun 30, 2025 | 36.10 Mn |
| Jun 30, 2025 | 36.10 Mn |
| Mar 31, 2025 | 6.75 Mn |
| Mar 31, 2025 | 6.75 Mn |
| Dec 31, 2024 | 7.17 Mn |
| Dec 31, 2024 | 7.17 Mn |
| Sep 30, 2024 | 7.49 Mn |
| Sep 30, 2024 | 7.49 Mn |
| Jun 30, 2024 | 7.43 Mn |
| Jun 30, 2024 | 7.43 Mn |
| Mar 31, 2024 | 5.41 Mn |
| Mar 31, 2024 | 5.41 Mn |